Raajit Rampal
Memorial Sloan Kettering Cancer Center · Memorial SloanKettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Raajit Rampal as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:27 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07886801 · A Study of Ropeg-Interferon in People With Polycythemia VeraMemorial Sloan Kettering Cancer Center · recruiting · Polycythemia Vera (PV), JAK2 Mutation · principal investigator
- N/ANCT07362225 · MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)MPN Research Foundation · recruiting · Polycythemia Vera, ET (Essential Thrombocythemia), Polycythemia Vera (PV) · principal investigator
- Ph1/Ph2NCT06773195 · A Study of Ruxolitinib in Combination With Ulixertinib in People With MyelofibrosisMemorial Sloan Kettering Cancer Center · recruiting · Myelofibrosis · principal investigator
- Ph1NCT05714072 · A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of MyelofibrosisMemorial Sloan Kettering Cancer Center · recruiting · Myelofibrosis Due to and Following Polycythemia Vera · principal investigator
- Ph2NCT03069326 · A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With MyelofibrosisMemorial Sloan Kettering Cancer Center · active not recruiting · Myelofibrosis · principal investigator
- Ph2NCT01668173 · HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ETMemorial Sloan Kettering Cancer Center · terminated · Myeloproliferative Neoplasms · principal investigator
- Ph1/Ph2NCT00382200 · Decitabine and Tretinoin in Treating Patients With Myelodysplastic SyndromesMemorial Sloan Kettering Cancer Center · completed · Myelodysplastic Syndromes · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:27 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Evaluation of genetic and epigenetic determinants of response in patients with accelerated and blast phase Myeloproliferative Neoplasm (MPNs)R21CA313410 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2026 · $444,590 awarded in 2026Same name and institution; not confirmed by an ID
- Investigation of the impact of pegylated Interferon on clonal trajectory and inflammatory cytokine production in MPN patientsR21CA267632 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2022 to 2023 · $202,732 awarded in 2023Same name and institution; not confirmed by an ID
- Genomic profiling and development of murine models of transformation of MPNsK08CA188529 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2014 to 2018 · $178,200 awarded in 2018Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:27 UTC. The ranking covers the 200 most relevant of 17 PubMed records, and a shared surname and initials can bring in a namesake. All 17 on PubMed
- 348 citationsRCR 13.2
- 152 citationsRCR 6.2
- Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.Blood Adv · 2018136 citationsRCR 4.2
- 130 citationsRCR 11.7
- Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.Blood Adv · 202088 citationsRCR 4.2
- MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis.J Clin Oncol · 202386 citationsRCR 7.8
- 82 citationsRCR 2.9
- Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.EBioMedicine · 201875 citationsRCR 2.5
- Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase.Blood Adv · 202066 citationsRCR 2.9
- Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.Nat Med · 202563 citationsRCR 15.9